Becocalcidiol

DB04891InvestigationalSmall molecule

Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

Mechanism: The mechanism of action of becocalcidiol in the treatment of psoriasis is accounted for by an antiproliferative activity for keratinocytes and the stimulation of epidermal cell differentiation.
Curator reviewed
Primary indication: For topical treatment of psoriasis and psoriatic disorders.Curator reviewed
Formula / weight: C₂₃H₃₆O₂ · 344.5307 g/mol (avg)
Code names: 2MBISP · DP-006 · QRX-101

Resolves to

Compound

Structure

InChIKeyQSLUXQQUPXBIHH-YHSKWIAJSA-NSMILESCC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

156Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Becocalcidiol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.